Start-up of the week: Inflection Biosciences

The figures around cancer are terrifying. In Ireland, it is the second most common cause of death, and one in three people will develop it in their lifetime.

Darren Cunningham and Michael O'Neill, co-founders of Inflection Biosciences. Photo: Keith Arkins

Inflection Biosciences

**What it does:** developing a targeted small molecule treatment for cancer

**Why it works:** "The company is a great example of an early-stage technology company with a highly experienced team that is leveraging the resources and discovery expertise of the leading global research institutes to commercialise innovative treatments for cancer." - **Brian O'Neill, manager of high potential start-ups, industrial and lifesciences at Enterprise Ireland**


The figures around cancer are terrifying. ...